173 related articles for article (PubMed ID: 28245539)
1. [A Case of Hydrocephalus Due to Brain Metastasis from Renal Cell Carcinoma Successfully Treated with Axitinib].
Shimura S; Koguchi D; Minamida S; Taoka Y; Iwamura M
Hinyokika Kiyo; 2017 Jan; 63(1):11-14. PubMed ID: 28245539
[TBL] [Abstract][Full Text] [Related]
2. [A Case of Renal Cell Carcinoma with Malignant Pleural Effusion Showing Marked Response to Axitinib].
Ishizuya Y; Okusa T; Hatano K; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K
Hinyokika Kiyo; 2016 Oct; 62(10):525-528. PubMed ID: 27919126
[TBL] [Abstract][Full Text] [Related]
3. [Metastatic Renal Cell Carcinoma in Paranasal Sinus for which Periodic Drug Withdrawal Schedule of Axitinib was Effective : A Case Report].
Arai Y; Ito K; Tachi K; Koga A; Shinchi Y; Masunaga A; Isono M; Asano T
Hinyokika Kiyo; 2016 Sep; 62(9):465-471. PubMed ID: 27760971
[TBL] [Abstract][Full Text] [Related]
4. Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report.
Koie T; Ohyama C; Okamoto A; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y
BMC Res Notes; 2013 Nov; 6():484. PubMed ID: 24267160
[TBL] [Abstract][Full Text] [Related]
5. Axitinib controlled metastatic renal cell carcinoma for 5 years.
Takayama T; Nagata M; Kai F; Sugiyama T; Ozono S
Jpn J Clin Oncol; 2013 Jul; 43(7):747-51. PubMed ID: 23667154
[TBL] [Abstract][Full Text] [Related]
6. [Continuation of Axitinib for Advanced Renal Cell Carcinoma by The Application of Homecare Urology - A Case Report and Literature Review].
Yazawa S; Kato Y; Nakahara J; Miyata T; Oya M
Gan To Kagaku Ryoho; 2018 Apr; 45(4):639-642. PubMed ID: 29650821
[TBL] [Abstract][Full Text] [Related]
7. Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.
Koie T; Ohyama C; Yoneyama T; Yamamoto H; Imai A; Hatakeyama S; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
BMC Urol; 2015 Apr; 15():32. PubMed ID: 25887125
[TBL] [Abstract][Full Text] [Related]
8. [A case of papillary renal cell carcinoma type 2 resistant to sunitinib responded to second line therapy with axitinib].
Ishii G; Hatano T; Endo K; Seki K; Yamada H; Kimura T; Egawa S
Nihon Hinyokika Gakkai Zasshi; 2014 Jul; 105(3):129-33. PubMed ID: 25158555
[TBL] [Abstract][Full Text] [Related]
9. Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
Takada M; Yasui T; Oka T; Shioyama W; Kuroda T; Nakai Y; Nishimura K; Mukai M; Fujita M
Int Heart J; 2018 Sep; 59(5):1174-1179. PubMed ID: 30158382
[TBL] [Abstract][Full Text] [Related]
10. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival following multidisciplinary treatment of metastatic sarcomatoid renal cell carcinoma: a case report.
Yaegashi H; Izumi K; Konaka H; Mizokami A; Namiki M
J Med Case Rep; 2015 Nov; 9():261. PubMed ID: 26582158
[TBL] [Abstract][Full Text] [Related]
12. Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial.
Karam JA; Devine CE; Fellman BM; Urbauer DL; Abel EJ; Allaf ME; Bex A; Lane BR; Thompson RH; Wood CG
BJU Int; 2016 Apr; 117(4):629-35. PubMed ID: 26033220
[TBL] [Abstract][Full Text] [Related]
13. Kidney cancer: progress and controversies in neoadjuvant therapy.
Posadas EM; Figlin RA
Nat Rev Urol; 2014 May; 11(5):254-5. PubMed ID: 24752207
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of pre-surgical axitinib for shrinkage of inferior vena cava thrombus in a patient with advanced renal cell carcinoma.
Sassa N; Kato M; Funahashi Y; Maeda M; Inoue S; Gotoh M
Jpn J Clin Oncol; 2014 Apr; 44(4):370-3. PubMed ID: 24571808
[TBL] [Abstract][Full Text] [Related]
15. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
[TBL] [Abstract][Full Text] [Related]
16. Axitinib-induced acute pancreatitis: a case report.
Péron J; Khenifer S; Potier V; Vitry T; Pasquet F; Rassat R; Pavic M
Anticancer Drugs; 2014 Apr; 25(4):478-9. PubMed ID: 24398664
[TBL] [Abstract][Full Text] [Related]
17. Axitinib in metastatic renal cell carcinoma.
Albiges L; Gizzi M; Carton E; Escudier B
Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.
Carmichael C; Lau C; Josephson DY; Pal SK
Clin Adv Hematol Oncol; 2012 May; 10(5):307-14. PubMed ID: 22706540
[TBL] [Abstract][Full Text] [Related]
20. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
Kitamura Y; Yoshii H; Nishimoto K; Shinchi Y; Tokonabe S; Takao M; Daido Y
Keio J Med; 2015; 64(4):62-4. PubMed ID: 26727578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
